Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature

The latest and newest discoveries for advanced and metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer are the three cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in association with endocrine therapy (ET). However, even if t...

Description complète

Détails bibliographiques

Auteurs principaux:	Ioana-Miruna Stanciu, Andreea Ioana Parosanu, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Cristina Mihaela Olaru, Cristina Florina Pirlog, Radu Constantin Vrabie, Cornelia Nitipir
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2023-03-01
Collection:	Diagnostics
Sujets:	CDK4/6 inhibitors advanced/metastatic breast cancer biomarkers of response progression on CDK4/6 inhibitors resistance mechanisms endocrine therapy
Accès en ligne:	https://www.mdpi.com/2075-4418/13/5/987
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!